1. 176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors. (December 2022) Authors: Italiano, A.; Saavedra Santa Gadea, O.; Papadopoulos, K.; Naing, A.; Gomez-Roca, C.A.; Mita, M.; Stein, M.; Rybicka, I.; van der Velden, M.; Zhang, P.; Smith, M.; Ivanova, O.; Loriot, Y. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) Authors: Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA. (12th June 2019) Authors: Samaniego, F.; Hollebecque, A.; Foss, F.; Lister, J.; Mita, M.; Wagner‐Johnston, N.; Dyer, M.; You, B.; Prica, A.; Hernandez‐Llizaliturri, F.; Ferraldeschi, R.; Chan, D.; Zhang, J.; Mehta, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗